Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic
effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in
combination with immune checkpoint inhibitors in HLA-A*02+ patients with recurrent, locally
advanced or metastatic human papillomavirus strain 16 positive (HPV16+) solid tumors. The
study includes patients with anal, rectal, cervical, head and neck, penile, vulvar, or
vaginal cancer.